NCT02728453 - SGLT2 Inhibition and Left Ventricular Mass | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 27, 2016

Primary Completion Date

September 25, 2017

Study Completion Date

September 27, 2017

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Empagliflozin

Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.

DRUG

Glimepiride

Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.

Trial Locations (1)

30625

Hannover Medical School, Hanover